An Investigation of Levetiracetam in Alzheimer ’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

DiscussionThis is the first study to evaluate if an anti-seizure medication can offer meaningful benefit to patients with Alzheimer ’s disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to rapidly progress to a larger study to establish whether levetiracetam may be a useful and cost-effective treatment for patients with Alzheimer’s disease.Trial registrationClinicalTrials.govNCT03489044. Registered on April 5, 2018.

Source: Trials - July 31, 2021 Category: Research Source Type: clinical trials